FRAX™ and the assessment of fracture probability in men and women from the UK
Tóm tắt
A fracture risk assessment tool (FRAX™) is developed based on the use of clinical risk factors with or without bone mineral density tests applied to the UK. The aim of this study was to apply an assessment tool for the prediction of fracture in men and women with the use of clinical risk factors (CRFs) for fracture with and without the use of femoral neck bone mineral density (BMD). The clinical risk factors, identified from previous meta-analyses, comprised body mass index (BMI, as a continuous variable), a prior history of fracture, a parental history of hip fracture, use of oral glucocorticoids, rheumatoid arthritis and other secondary causes of osteoporosis, current smoking, and alcohol intake 3 or more units daily. Four models were constructed to compute fracture probabilities based on the epidemiology of fracture in the UK. The models comprised the ten-year probability of hip fracture, with and without femoral neck BMD, and the ten-year probability of a major osteoporotic fracture, with and without BMD. For each model fracture and death hazards were computed as continuous functions. Each clinical risk factor contributed to fracture probability. In the absence of BMD, hip fracture probability in women with a fixed BMI (25 kg/m2) ranged from 0.2% at the age of 50 years for women without CRF’s to 22% at the age of 80 years with a parental history of hip fracture (approximately 100-fold range). In men, the probabilities were lower, as was the range (0.1 to 11% in the examples above). For a major osteoporotic fracture the probabilities ranged from 3.5% to 31% in women, and from 2.8% to 15% in men in the example above. The presence of one or more risk factors increased probabilities in an incremental manner. The differences in probabilities between men and women were comparable at any given T-score and age, except in the elderly where probabilities were higher in women than in men due to the higher mortality of the latter. The models provide a framework which enhances the assessment of fracture risk in both men and women by the integration of clinical risk factors alone and/or in combination with BMD.
Tài liệu tham khảo
World Health Organization (1994) Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. WHO Technical Report Series 843. WHO, Geneva
Marshall D, Johnell O, Wedel JJ (1996) Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. Br Med J 312:1254–1259
Johnell O, Kanis JA, Oden A, Johansson H et al (2005) Predictive value of bone mineral density for hip and other fractures. J Bone Miner Res 20:1185–1194
Kanis JA, Johnell O, Oden A, Jönsson B, De Laet C, Dawson A (2000) Risk of hip fracture according to World Health Organization criteria for osteopenia and osteoporosis. Bone 27:585–590
Hui SL, Slemenda CW, Johnston CC (1988) Age and bone mass as predictors of fracture in a prospective study. J Clin Invest 81:1804–1809
De Laet CEDH, van Hout BA, Burger H, Hofman A, Pols HAP (1997) Bone density and risk of hip fracture in men and women: cross sectional analysis. Br Med J 315:221–225
Kanis JA, Johnell O, Oden A, Jönsson B, Dawson A, Dere W (2000) Risk of hip fracture derived from relative risks: an analysis applied to the population of Sweden. Osteoporos Int 11:120–127
De Laet C, Oden A, Johansson H, Johnell O, Jonsson B, Kanis JA (2005) The impact of the use of multiple risk indicators for fracture on case-finding strategies: a mathematical approach. Osteoporos Int 16:313–318
Kanis JA, Johnell O, Oden A, De Laet C, Jonsson B, Dawson A (2002) Ten-year risk of osteoporotic fracture and the effect of risk factors on screening strategies. Bone 30:251–258
Kanis JA, Johansson H, Oden A et al (2004) A family history of fracture and fracture risk. Bone 35:1029–1037
Kanis JA, Johansson H, Oden A et al (2004) A meta-analysis of prior corticosteroid use and fracture risk. J Bone Miner Res 19:893–899
Kanis JA, Johnell O, De Laet C et al (2004) A meta-analysis of previous fracture and subsequent fracture risk. Bone 35:375–382
De Laet C, Kanis JA, Oden A et al (2005) Body mass index as a prediction of fracture risk. A meta-analysis. Osteoporos Int 16:1330–1338
Kanis JA, Johansson H, Johnell O et al (2005) Alcohol intake as a risk factor for fracture. Osteoporos Int 16:737–742
Kanis JA, Johansson H, Oden A et al (2005) A meta-analysis of milk intake and fracture risk: low utility for case finding. Osteoporos Int 16:799–804
Kanis JA, Johnell O, Oden A et al (2005) Smoking and fracture risk: a meta-analysis. Osteoporos Int 16:222–228
Kanis JA, Oden A, Johnell O et al (2007) The use of clinical risk factors enhances the performance of BMD in the prediction of hip and osteoporotic fractures in men and women. Osteoporos Int 18:1033–1046
Black DM, Steinbuch M, Palermo L et al (2001) An assessment tool for predicting fracture risk in postmenopausal women. Osteoporos Int 12:519–528
Kanis JA, Gluer C-C, for the Committee of Scientific Advisors, International Osteoporosis Foundation (2000) An update on the diagnosis and assessment of osteoporosis with densitometry. Osteoporos Int 11:192–202
Kanis JA (2002) Diagnosis of osteoporosis and assessment of fracture risk. Lancet 359:1929–1936
Ramsay LE, Haq IU, Jackson PR, Yeo WW, Pickin DM, Payne JN (1996) Targeting lipid-lowering drug therapy for primary prevention of coronary artery disease: an updated Sheffield table. Lancet 348:387–388
Ramsay LE, Haq IU, Jackson PR, Yeo WW (1996) The Sheffield table for primary prevention of coronary heart disease. Corrected. Lancet 348:1251–1252
Conroy RM, Pyörälä K, Fitzgerald AP et al (2003) Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Europ Heart J 11:987–1003
UKPDS Group (2001) The UKPDS Risk Engine: a model for the risk of coronary heart disease in type 2 diabetes (UKPDS 56). Clin Sci 101:671–679
UKPDS Group (2002) Risk of Stroke in Type 2 Diabetes Estimated by the UK Prospective Diabetes Study Risk Engine (UKPDS 60). Stroke 33:1776–1781
Breslow NE, Day NE (1987) Statistical methods in cancer research, vol 2. IARC Scientific Publications, no 32, Lyon 131–135
Oden A, Dawson A, Dere W, Johnell O, Jonsson B, Kanis JA (1988) Lifetime risk of hip fracture is underestimated. Osteoporos Int 8:599–603
Singer BR, McLauchlan GJ, Robinson CM, Christie J (1998) Epidemiology of fractures in 15,000 adults. The influence of age and gender. J Bone Joint Surg 80B:243–248
DeLusignan S, Valentin T, Chan T et al (2004) Problems with primary care data quality: Osteoporosis as an exemplar. Informatics in Primary Care 12:147–156
Kanis J, Brazier J, Stevenson M, Calvert W, Jones ML (2002) Treatment of established osteoporosis: a systematic review and cost-utility analysis. Health Technol Ass 6:1–146
Kanis JA, Oden A, Johnell O, Jonsson B, de Laet C, Dawson A (2001) The burden of osteoporotic fractures: a method for setting intervention thresholds. Osteoporos Int 12:417–427
Kanis JA, Johnell O, Oden A et al (2000) Long-term risk of osteoporotic fracture in Malmö. Osteoporos Int 11:669–674
Tuppurainen M, Kroger H, Honkanen R et al (1995) Risks of perimenopausal fractures - a prospective population-based study. Acta Obstetr Gynecol Scand 74:624–628
Kanis JA, McCloskey EV, Powles T, Paterson AH, Ashley S, Spector T (1999) A high incidence of vertebral fracture in women with breast cancer. Br J Cancer 79:1179–1181
Melton LJ III, Khosla S, Malkasian GD, Achenbach SJ, Oberg AL, Riggs BL (2003) Fracture risk after bilateral oophorectomy in elderly women. J Bone Miner Res 18:900–905
Melton LJ III, Alothman KI, Khosla S, Achanbach SJ, Oberg AL, Zinake H (2003) Fracture risk following bilateral orchidectomy. J Urol 169:1747–1750
Stanley I II, Selmatt BP, Poses RM, Deiss WP (1991) Does hypogonadism contribute to the occurrence of a minimal trauma hip fracture in elderly men? J Amer Geriatric Soc 39:766–771
Wuster C, Abs R, Bengtsson BA, Benmarker H, Feld B, Rasmussen U et al (2001) The influence of growth hormone deficiency, growth hormone replacement therapy, and other aspects of hypopituitarism on fracture rate and bone mineral density. J Bone Miner Res 16:398–405
Rigotti NA, Neer RM, Skates SJ, Herzog DB, Nussbaum SR (1991) The clinical course of osteoporosis in anorexia nervosa. A longitudinal study of cortical bone mass. JAMA 265:1133–1138
Gillberg C, Rastam M, Gillberg IC (1994) Anorexia nervosa: physical health and neurodevelopment at 16 and 21 years. Dev Med Child Neurol 36:567–575
Vestergaard P, Mosekilde L (2002) Fracture risk in patients with celiac disease, Crohn’s disease, and ulcerative colitis: a nationwide follow-up study of 16,416 patients in Denmark. Am J Epidemiol 156:1–10
Bernstein CN, Blanchard JF, Leslie W, Wajda A, Yu BN (2000) The incidence of fracture among patients with inflammatory bowel disease: a population-based cohort study. Ann Intern Med 133:795–799
Loftus EV, Crowson C, Sandborn WJ, Tremaine WJ, O’Fallon WM, Melton LJ III (2000) Long-term fracture risk in patients with Crohn’s disease: a population-based study in Olmsted County, Minnesota. Gastroenterol 123:468–475
Van Staa T-P, Cooper C, Brusst LS, Leufkens H, Javaid MK, Arden NK (2003) Inflammatory bowel disease and the risk of fracture. Gastroenterol 125:1591–1597
Vestergaard P, Krogh K, Rejnmark L, Mosekilde L (1998) Fracture rates and risk factors for fractures in patients with spinal cord injury. Spinal Cord 36:790–796
Vestergaard P, Glerup IT, Steffensen BF, Rejnmark I, Rabbek J, Mosekilde I (2001) Fracture risk in patients with muscular dystrophy and spinal muscular atrophy. J Rehabilitation Med 33:150–155
Johnell O, Melton LJ III, Atkinson EJ, O’Fallon WM, Kurland LT (1992) Fracture risk in patients with Parkinsonism: a population-based study in Olmsted County, Minnesota. Age Ageing 21:32–38
Dennis MS, Lo KM, McDowall M, West T (2002) Fractures after stroke: frequency, types and associations. Stroke 33:728–734
Kanis JA, Oden A, Johnell O (2001) Acute and long-term increase in fracture risk after hospitalisation for stroke. Stroke 32:702–706
Donnelly S, Doyle DV, Denton A, Roffe I, McCloskey EV, Spector TD (1994) Bone mineral density and vertebral compression fracture rates in ankylosing spondylitis. Ann Rheum Dis 53:117–121
Royal College of Physicians (2002) Glucocorticoid-induced osteoporosis. Guidelines on prevention and treatment. Bone and Tooth Society of Great Britain, National Osteoporosis Society and Royal College of Physicians. Royal College of Physicians London UK
Ramsey-Goldman R, Dunn JE, Dunlop DD (1999) Increased risk of fracture in patients receiving solid organ transplants. J Bone Miner Res 14:456–463
Vantour LM, Melton LJ 3rd, Clarke I, Achenbach SJ, Oberg AL, McCarthy JT (2004) Long-term fracture risk following renal transplantation: a population-based study. Osteoporos Int 15:160–167
Shane E, Papadoupoulos A, Staron RB et al (1999) Bone loss and fracture after lung transplantation. Transplantation 68:220–227
Nicodemus KK, Folsom AR, Iowa Women’s Health Study (2001) Type 1 and type 2 diabetes and incident hip fractures in postmenopausal women. Diabetes Care 24:1192–1197
U.S. Department of Health and Human Services (2004) Bone health and osteoporosis: a report of the Surgeon General. Rockville, MD, U.S. Department of Health and Human Services, Office of the Surgeon General
Vestergaard P, Rejnmark L, Mosekilde L (2005) Relative fracture risk in patients with diabetes mellitus, and the impact of insulin and oral antidiabetic medication on relative fracture risk. Diabetologia 48:1292–1299
Schwartz AV, Sellmeyer DE, Ensrud KE et al (2001) Older women with diabetes have an increased risk of fracture: a prospective study. J Clin Endocrinol Metab 86:32–38
Vestergaard P, Mosekilde L (2003) Hyperthyroidism, bone mineral, and fracture risk - a meta-analysis. Thyroid 13:585–593
Vestergaard P, Rejnmark L, Weeke J, Mosekilde L (2000) Fracture risk in patients treated with hyperthyroidism. Thyroid 10:341–348
Vestergaard P, Mosekilde L (2002) Fractures in patients with hyperthyroidism and hypothyroidism: a nationwide follow-up study in 16,249 patients. Thyroid 12:411–419
Melton LJ 3rd, Ardila E, Crowson CS, O’Fallon WM, Khosla S (2000) Fractures following thyroidectomy in women: a population-based cohort study. Bone 27:695–700
Bauer DC, Ettinger B, Nevitt MC, Stone KL, Study of Osteoporotic Fractures Research Group (2001) Risk for fracture in women with low serum levels of thyroid-stimulating hormone. Ann Intern Med 134:561–568
Looker AC, Wahner HW, Dunn WL, Calvo MS, Harris TB, Heyse SP (1998) Updated data on proximal femur bone mineral levels of US adults. Osteoporos Int 8:468–486
Burger H, de Laet CE, Weel AE, Hofman A, Pols HA (1999) Added value of bone mineral density in hip fracture risk scores. Bone 25:369–374
Albrand G, Munoz F, Sornay RE, Duboeuf F, Delmas PD (2001) Independent predictors of all osteoporosis-related fractures in healthy postmenopausal women: The OFELY Study. Bone 32:78–85
Carroll J, Testa M, Erat K, LeBoff M, Fuleihan G-EH (1997) Modelling fracture risk using bone density, age, and years since menopause. Am J of Preventive Med 13:447–452
Dargent-Molina P, Douchin MN, Cormier C, Meunier PJ, Bréart G (2002) Use of clinical risk factors in elderly women with low bone mineral density to identify women at higher risk of hip fracture: The EPIDOS prospective study. Osteoporos Int 13:593–599
Girman CJ, Chandler JM, Zimmerman S et al (2002) Prediction of fracture in nursing home residents. J Am Geriatr Soc 50:1341–1347
Honkanen RJ, Honkanen K, Kroger H, Alhava E, Tuppurainen M, Saarikoski S (2000) Risk factors for perimenopausal distal forearm fracture.Osteoporos Int 11:265–270
Leslie WD, Metge C, Salamon EA, Yuen CK (2002) Bone mineral density testing in healthy postmenopausal women. The role of clinical risk factor assessment in determining fracture risk. J Clin Densitom 5:117–130
Miller PD, Barlas S, Brenneman SK et al (2004) An approach to identifying osteopenic women at increased short-term risk of fracture. Arch Int Med 164:1113–1120
Westfall G, Littlefield R, Heaton A, Martin S (2001) Methodology for identifying patients at high risk for osteoporotic fracture. Clin Therap 23:1570–1588
Colón-Emeric CS, Pieper CF, Artz MB (2002) Can historical and functional risk factors be used to predict fractures in community-dwelling older adults? Development and validation of a clinical tool. Osteoporos Int 13:955–961
van Staa TP, Leufkens H-GM, Cooper C (2002) Utility of medical and drug history in fracture risk prediction among men and women. Bone 31:508–514
Van Staa T-P, Geusens P, Pols HAP, De Laet C, Leufkens HCM, Cooper C (2005) A simple score for estimating the long-term risk of fracture in patients using oral glucocorticoids. Quart Jl Med 98:191–198
McGrother CW, Donaldson M-MK, Clayton D, Abrams KR, Clarke M (2002) Evaluation of a hip fracture risk score for assessing elderly women: the Melton Osteoporotic Fracture (MOF) study. Osteoporos Int 13:89–96
Walter LC, Lui LY, Eng C, Covinsky KE (2003) Risk of hip fracture in disabled community-living older adults. J Am Geriatr Soc 51:50–55
Food and Drug Administration (1994) Guidelines for preclinical and clinical evaluation of agents used in the prevention or treatment of postmenopausal osteoporosis. Division of Metabolism and Endocrine Drug Products, Rockville, MD
Committee for Medicinal Products for Human Use (CHMP) (2006) Guideline on the evaluation of medicinal products in the treatment of primary osteoporosis. Ref CPMP/EWP/552/95Rev.2. London, CHMP, Nov
Saag KG, Emkey R, Schnitzer TJ et al (1998) Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. Glucocorticoid-induced Osteoporosis Intervention Study Group. N Engl J Med 339:292–299
Adachi JD, Saag KG, Delmas PD et al (2001) Two year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids: a randomised, double-blind, placebo-controlled extension trial. Arthr Rheum 44:202–211
Reginster JY, Minne HW, Sorensen OH et al (2000) Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral efficacy with risedronate therapy (VERT) study group. Osteoporos Int 11:83–91
Kanis JA, Barton I, Johnell O (2005) Risedronate decreases fracture risk in patients selected solely on the basis of prior vertebral fracture. Osteoporos Int 16:475–482
McCloskey EV, Selby P, Davies M et al (2004) Clodronate reduces vertebral fracture risk in women with post-menopausal or secondary osteoporosis: results of a double blind placebo-controlled 3 year study. J Bone Miner Res 19:728–736
Roux C, Reginster JY, Fechtenbaum J et al (2006) Vertebral fracture risk reduction with strontium ranelate in women with post-menopausal osteoporosis is independent of baseline risk factors. J Bone Miner Res 21:536–542
Marcus R, Wang O, Satterwhite J et al (2003) The skeletal response to teriparatide is largely independent of age, initial bone mineral density and prevalent vertebral fractures in postmenopausal women with osteoporosis. J Bone Miner Res 18:18–23
Johnell O, Kanis JA, Black DM et al (2004) Association between baseline risk factors and vertebral fracture risk in the Multiple Outcomes of Raloxifene Evaluation (MORE) study. J Bone Miner Res 19:764–772
McClung MR, Geusens P, Miller PD et al (2001) Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. New Engl J Med 344:333–340
Cummings SR, Black DM, Thompson D et al (1998) Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA 280:2077–2082
Davison KS, Siminoski K, Chik C, Jen H, Warshawski R, Lee K (2003) Impact of height loss due to vertebral fractures on body mass index. J Bone Miner Res 18(Suppl 2):S243
Midanik LT (1988) Validity of self-reported alcohol use: a literature review and assessment. Br J Addict 83:1019–1030
Standing Medical Advisory Committee to the Secretaries of State for Health and for Wales (1989) Drinking problems. A challenge for every doctor. HMSO, London
Van Staa TP, Leufkens HGM, Abenhaim L, Zhang B, Cooper C (2000) Fracture and oral corticosteroids: relationship to daily and cumulative dose. Rheumatol 39:1383–1389
Delmas PD, Genant HK, Crans GG et al (2003) Severity of prevalent vertebral fractures and the risk of subsequent vertebral and nonvertebral fractures: results from the MORE trial. Bone 33:522–532
Kanis JA, Adams J, Borgström B et al (2008) The cost-effectiveness of alendronate in the management of osteoporosis. Bone, (in press)
Kanis JA, Johnell O, De Laet C, Jonsson B, Oden A, Oglesby A (2002) International variations in hip fracture probabilities: implications for risk assessment. J Bone Miner Res 17:1237–1244
World Health Organization (2008) Assessment of osteoporosis at the primary health care level. WHO, Geneva (in press)
Kanis JA, on behalf of the World Health Organization Scientific Group (2008) Assessment of osteoporosis at the primary health-care level. Technical Report. WHO Collaborating Centre, University of Sheffield, UK (in press)